<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01855334</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DK096189</org_study_id>
    <nct_id>NCT01855334</nct_id>
  </id_info>
  <brief_title>L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD</brief_title>
  <acronym>LAST-D</acronym>
  <official_title>A Randomized, Controlled Trial of L-arginine and Spironolactone in Dialysis-dependant End Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease is the primary cause of death in patients with end stage renal disease
      (ESRD). New research suggests that the high risk of death may be partly due to high levels of
      fibrosis and a loss of small blood vessels in the heart of patients with dialysis-dependent
      ESRD. This study is designed to compare the effects of two different drugs, spironolactone
      and L-arginine, with placebo on structure and function of the heart in individuals with
      dialysis-dependent ESRD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that that abnormalities in aldosterone and nitric oxide (NO) homeostasis
      contribute to the progression of microvascular disease and myocardial fibrosis in ESRD and
      that agents designed to restore normal aldosterone and NO homeostasis will improve
      microvascular and diastolic cardiac function in the heart of individuals with dialysis
      dependent ESRD. We will test 2 specific agents: The mineralocorticoid receptor blocker
      spironolactone; and L-arginine, an agent which improves NO bioavailability. Two specific aims
      will be addressed using a prospective, double-blinded, 2x2 factorial trial in dialysis
      dependent patients with ESRD. Subjects will be randomized to placebo, spironolactone plus
      placebo, L-arginine plus placebo, or combination spironolactone and L-arginine therapy.
      Diastolic cardiac function will be assessed using tissue Doppler index (TDI) determined
      mitral annular velocities (E') on LV echocardiography, and microvascular supply will be
      assessed using CFR—the ratio of hyperemic to resting myocardial blood flow—measured by
      positron emission tomography (PET) scans at baseline, 2 weeks and after 9 months of
      randomized therapy.

      This randomized trial of spironolactone and L-arginine will provide important data about the
      contributions of aldosterone and NO to the pathogenesis of cardiovascular disease in ESRD,
      will demonstrate the therapeutic potential of L-arginine and spironolactone as as targeted
      cardiovascular therapies for use in ESRD, and will provide important insights into the
      underlying pathophysiology of cardiovascular disease in ESRD. The results generated will
      provide the data needed to design large-scale trials testing whether spironolactone or
      L-arginine can improve mortality or cardiovascular outcomes in ESRD.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    change of funding leading to major redesign
  </why_stopped>
  <start_date type="Anticipated">September 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in coronary Flow Reserve (PET)</measure>
    <time_frame>Between baseline and 9 months</time_frame>
    <description>Coronary flow reserve will be measured using rest and stress 13N ammonia myocardial positron emission tomography (PET) at baseline and 9 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in left ventricular diastolic function</measure>
    <time_frame>Between baseline and 9 months</time_frame>
    <description>Left ventricular diastolic function will be measured using mitral annular E' on tissue doppler index echocardiography at baseline and 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between coronary flow reserve (CFR) and tissue doppler index (E')</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in resting myocardial blood flow</measure>
    <time_frame>Between baseline and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular mass index</measure>
    <time_frame>Between baseline and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coronary vascular resistance</measure>
    <time_frame>Between 0 and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between change in coronary flow reserve (CFR) and change in diastolic function-tissue doppler index (E')</measure>
    <time_frame>Between baseline and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in early diastolic function (E')</measure>
    <time_frame>Between baseline and 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined cardiovascular safety</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Combined rate of death, myocardial infarction, stroke, or hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>Up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperkalemia</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Hyperkalemia requiring extra dialysis, adjustment in dialysate potassium, or discontinuation of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Symptomatic or intradialytic hypotension up to 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in early coronary flow reserve</measure>
    <time_frame>Between baseline and 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hyperemic myocardial blood flow</measure>
    <time_frame>Between baseline and 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Spironolactone + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone 25 mg by mouth daily + Placebo L-arginine-liquid formulation by mouth 3 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo spironolactone-1 tablet by mouth daily + Placebo L-arginine liquid formulation by mouth 3 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone + L-arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone 25 mg daily + L-arginine 3 grams orally 3 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-arginine + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-arginine 3 grams by mouth 3 times daily + Placebo spironolactone 1 tablet by mouth daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <arm_group_label>Spironolactone + Placebo</arm_group_label>
    <arm_group_label>Spironolactone + L-arginine</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-arginine</intervention_name>
    <arm_group_label>Spironolactone + L-arginine</arm_group_label>
    <arm_group_label>L-arginine + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Spironolactone + Placebo</arm_group_label>
    <arm_group_label>Double Placebo</arm_group_label>
    <arm_group_label>L-arginine + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic dialysis therapy for End Stage Renal Disease

          -  Age 21-85

        Exclusion Criteria:

          -  Hyperkalemia requiring unscheduled dialysis within 3 months

          -  Pre-dialysis potassium ≥6.5 meq/L within 3 months

          -  Hypotension defined as SBP &lt;100

          -  Recurrent intra-dialytic hypotension defined as recurrent cramping, light-headedness,
             or hypotension requiring infusion of saline or other intervention or otherwise
             limiting ability to achieve dry weight. Or SBP &lt;80

          -  History of myocardial infarction

          -  History of coronary artery bypass surgery

          -  Non revascularized coronary disease &gt;90%

          -  Mitral valve repair or replacement

          -  Severe mitral valve disease

          -  Renal transplant expected within 9 months

          -  Expected survival &lt; 9 months

          -  Pregnant

          -  Prisoners

          -  Unable to provide consent

          -  Allergy to spironolactone or L-arginine

          -  Digitalis use

          -  1st or 2nd degree heart block
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>021114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>David Charytan M.D.</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>ESRD</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>spironolactone</keyword>
  <keyword>L-arginine</keyword>
  <keyword>myocardial perfusion</keyword>
  <keyword>coronary flow reserve</keyword>
  <keyword>diastolic function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

